

# T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/T6B91D730D58EN.html>

Date: December 2019

Pages: 73

Price: US\$ 3,500.00 (Single User License)

ID: T6B91D730D58EN

## Abstracts

T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H2 2019

### SUMMARY

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H2 2019, outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 6 and 1 respectively. Similarly, the universities portfolio in Phase 0 stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Hematological Disorders, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Solid Tumor, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Multiple Sclerosis, Rheumatoid Arthritis, Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma, B-Cell Chronic Lymphocytic Leukemia, Colon Cancer, Colorectal Cancer, Gastrointestinal Radiation Toxicity, Hemophagocytic Lymphohistiocytosis, Inflammatory Bowel Disease,

Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Psoriasis, Psoriatic Arthritis, Sicca Syndrome (Sjogren), Skin And Soft Tissue Infections, Stem Cell Transplantation, Systemic Lupus Erythematosus and Uveitis.

Furthermore, this report also reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)

The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects

The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development

Alpine Immune Sciences Inc

Atox Bio Ltd

Avacta Life Sciences Ltd

Bristol-Myers Squibb Co

Five Prime Therapeutics Inc

Imugene Ltd

OSE Immunotherapeutics

Regeneron Pharmaceuticals Inc

TheraMAB LLC

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles

ALPN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALPN-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target CD28 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FPT-155 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FR-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Target ICOS, CD28 and NCR3LG1 for Colon Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Iulizumab pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CD278, CD28 and HER2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins to Agonize CD28 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-5678 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reltecimod sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAB-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD28 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Discontinued Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Product Development

Milestones

Featured News & Press Releases

Dec 09, 2019: Alpine Immune Sciences presents ALPN-101 phase 1 healthy volunteer study data and details of upcoming phase I/II BALANCE GVHD study at the 61st American Society of Hematology annual meeting

Nov 12, 2019: Alpine Immune Sciences presents new ALPN-101 preclinical data at the 2019 American College of Rheumatology (ACR) Annual Meeting

Nov 09, 2019: Five Prime Therapeutics presents initial safety data from the phase 1 trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting

Nov 08, 2019: Alpine Immune Sciences presents new preclinical data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

Nov 06, 2019: Alpine Immune Sciences announces oral presentation of ALPN-101 at the 61st American Society of Hematology Annual Meeting and Exposition

Oct 30, 2019: Alpine Immune Sciences completes enrollment of phase I study of ALPN-101 and announces third quarter conference call

Oct 02, 2019: Alpine Immune Sciences announces upcoming scientific presentation of ALPN-101 at ACR/ARHP 2019 Annual Meeting

Oct 02, 2019: Alpine Immune Sciences announces upcoming scientific presentation on ALPN-202 at SITC 2019 Annual Meeting

Jun 18, 2019: Atox Bio announces exercise by BARDA of next option period to support continued development of reltecimod for NSTI

Apr 09, 2019: OSE Immunotherapeutics announces issuance of Canadian patent and notice of allowance of U.S. patent protecting CD28-Antagonist Immunotherapy FR104

Feb 19, 2019: Alpine Immune Sciences presents preclinical ALPN-101 GvHD data at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings)

Feb 14, 2019: Atox Bio announces appointment of Robert Greif as chief commercial officer

Feb 12, 2019: Alpine Immune treats first patient in Phase I trial of ALPN-101

Dec 03, 2018: Alpine Immune sciences showcases key preclinical data at 60th

American Society of Hematology Annual Meeting and Exposition  
Nov 29, 2018: Alpine Immune Sciences announces ALPN-101 data to be included in  
oral presentation at 60th American Society of Hematology Annual Meeting and  
Exposition

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indications, H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by Alpine Immune Sciences Inc, H2 2019  
Pipeline by Atox Bio Ltd, H2 2019  
Pipeline by Avacta Life Sciences Ltd, H2 2019  
Pipeline by Bristol-Myers Squibb Co, H2 2019  
Pipeline by Five Prime Therapeutics Inc, H2 2019  
Pipeline by Imugene Ltd, H2 2019  
Pipeline by OSE Immunotherapeutics, H2 2019  
Pipeline by Regeneron Pharmaceuticals Inc, H2 2019  
Pipeline by TheraMAB LLC, H2 2019  
Dormant Projects, H2 2019  
Discontinued Products, H2 2019



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Top 10 Indications, H2 2019  
Number of Products by Mechanism of Actions, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Routes of Administration, H2 2019  
Number of Products by Stage and Routes of Administration, H2 2019  
Number of Products by Molecule Types, H2 2019  
Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Alpine Immune Sciences Inc  
Atox Bio Ltd  
Avacta Life Sciences Ltd  
Bristol-Myers Squibb Co  
Five Prime Therapeutics Inc  
Imugene Ltd  
OSE Immunotherapeutics  
Regeneron Pharmaceuticals Inc  
TheraMAB LLC

## I would like to order

Product name: T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/T6B91D730D58EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T6B91D730D58EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970